Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Beersheva Mental Health Center National Alliance for Research on Schizophrenia and Depression |
---|---|
Information provided by: | Beersheva Mental Health Center |
ClinicalTrials.gov Identifier: | NCT00140192 |
Creatine plays a pivotal role in brain energy homeostasis. Creatine supplementation is widely used in enhancing sports performance, and has been tried in the treatment of neurological, neuromuscular and atherosclerotic disease with a paucity of side effects.
Dechent et al (1999) studied the effect of oral creatine supplementation for 4 wk demonstrating a statistically significant increase of mean concentration of total creatine across brain regions. These findings suggest the possibility of using oral creatine supplementation to modify brain high-energy phosphate metabolism in subjects with various brain disorders, including schizophrenia and major depression. Recently, Rae et al (2003) reported that creatine supplementation for 6 weeks had a significant positive effect on both working memory and Raven matrices. Several independent lines of evidence suggest the possible involvement of altered cerebral energy metabolism in schizophrenia.
We are performing a double blind cross-over study of creatine in schizophrenia.
Forty patients will be treated with creatine for 3 months in a double-blind crossover design. Rating scales will include scales for assessing negative and positive symptoms of schizophrenia, clinical global impressions scale, scales for side–effects and a cognitive battery
Creatine effects on brain energy metabolism and its possible cognitive enhancing properties raise the possibility of developing a new therapeutic strategy in schizophrenia focusing on treating metabolic hypoactive brain areas including frontal regions.
Condition | Intervention | Phase |
---|---|---|
Schizophrenia |
Drug: creatine |
Phase III |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Double-Blind, Placebo Control, Parallel Assignment |
Official Title: | Creatine as a New Treatment for Schizophrenia:A Double-Blind Trial |
Estimated Enrollment: | 40 |
Study Start Date: | September 2004 |
Estimated Study Completion Date: | September 2006 |
Ages Eligible for Study: | 18 Years to 60 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Israel | |
Beersheva Mental Health Center | Recruiting |
Beersheva, Israel | |
Contact: Alex Kaptsan, MD 972-8-6401602 akaptsan@bgu.ac.il | |
Contact: RH Belmaker, MD 972-8-6401602 belmaker@bgu.ac.il | |
Sub-Investigator: Alex Kaptsan, MD | |
Principal Investigator: Joseph Levine, MD |
Study Director: | RH Belmaker, MD | Ben Gurion University of the Negev + Beersheva Mental Health Center |
Study ID Numbers: | BMHC-3835 |
Study First Received: | August 31, 2005 |
Last Updated: | October 9, 2006 |
ClinicalTrials.gov Identifier: | NCT00140192 |
Health Authority: | Israel: Israeli Health Ministry Pharmaceutical Administration |
creatine metabolism schizophrenia energy metabolism |
Schizophrenia Mental Disorders Psychotic Disorders Schizophrenia and Disorders with Psychotic Features |